Current TSPAN-targeting therapies in hematologic malignancies
| Therapeutic . | Target and effects . | Model . | Reference . |
|---|---|---|---|
| Anti-CD82 | CD82: mobilizing agent, potentiates effects of anticancer therapy | Preclinical | 69 |
| 5A6 | CD81: mAb selectively kills B-cell lymphoma cells via direct cell death and innate immune system activation | Preclinical | 67 |
| PSB202 | CD37-CD20: bifunctional mAb pair to enable direct killing of B cells in lymphomas | Clinical | NCT05003141 |
| CAR-37 | CD37: CAR T cells for CD37+ hematologic malignancies | Clinical | NCT04136275 |
| Therapeutic . | Target and effects . | Model . | Reference . |
|---|---|---|---|
| Anti-CD82 | CD82: mobilizing agent, potentiates effects of anticancer therapy | Preclinical | 69 |
| 5A6 | CD81: mAb selectively kills B-cell lymphoma cells via direct cell death and innate immune system activation | Preclinical | 67 |
| PSB202 | CD37-CD20: bifunctional mAb pair to enable direct killing of B cells in lymphomas | Clinical | NCT05003141 |
| CAR-37 | CD37: CAR T cells for CD37+ hematologic malignancies | Clinical | NCT04136275 |
CAR, chimeric antigen receptor.